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A Policy in Flux: New York State’s
Evolving Approach to Human Subjects
Research Involving Individuals
Who Lack Consent Capacity
Valerie Gutmann Koch

D

espite existing federal and state law and
regulation, new human subjects research
(HSR) scandals involving “vulnerable” populations continue to surface.1 Although existing oversight mechanisms were enacted to ensure voluntary
informed consent for participants and institutional
review board (IRB) oversight of HSR, these laws
and regulations do not provide any special oversight
mechanisms or protections to ensure the ethical and
safe inclusion of cognitively impaired adults. The
absence of rules to ensure consistently ethical conduct
of research involving adults who lack consent capacity
may either lead to exploitation of this vulnerable population or the dearth of important research into the
broad range of diseases that impair cognition. In other
words, while some institutions and investigators are
conducting research with this group without guidance,
others are taking an extremely conservative approach
and are excluding these individuals from research.
Without safeguards that are adequate and robust but
not overly burdensome, conducting research involving
this population is ethically and legally challenging.
In the state of New York, efforts have been made to
regulate research involving individuals who lack consent capacity, particularly in response to the state’s
checkered history of ensuring the protection of this
particular population.2 In 1990, the New York State
Office of Mental Health promulgated regulations to
govern research that occurs at its facilities. However,
these regulations were overturned because a New York
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State court held that the agency did not have authority to make rules to oversee human subjects research.
Eight years later, the New York State Department of
Health – the agency with the authority to promulgate
regulations governing HSR – commissioned a work
group to develop regulations authorizing research
involving individuals with decisional incapacity. However, for political and other reasons, these proposed
regulations were never acted upon.
In January 2014, the New York State Task Force
on Life and the Law released its Report and Recommendations for Research with Human Subjects Who
Lack Consent Capacity, in an effort to ensure the ethical conduct of research involving cognitively impaired
adults. The report is the result of a multi-year effort to
respond to appeals for guidance from New York State
IRBs, investigators, and research institutions on how
to conduct ethical research involving adults who lack
consent capacity. It represents the most recent step in
a decades-long process across New York State agencies and courts to develop oversight mechanisms that
are appropriately sensitive to the fine line between
protecting a vulnerable population and impeding the
advancement of research.
As a practical matter, the Task Force’s report may
have limited direct application. The report – and, for
that matter, any New York State action – only applies
to human subjects research conducted in the state
that is not subject to federal oversight. The federal
Common Rule governs human subjects research that
is supported by federal funding, is conducted by the
federal government, or is overseen by a federal agency
— in other words, the vast majority of human subjects
research conducted in the United States. New York
State’s Public Health Law only applies to research
not covered by federal law.3 Thus, the Act applies to a
383
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minority of research activity in the state, because most
research conducted in New York is either federally
funded or otherwise subject to federal oversight.4

capacity in research due to concern that courts assessing the validity of new regulations would impose similar requirements in the future.

I. OMH Regulations and T.D. v. N.Y. State
Office of Mental Health

II. New York State Advisory Work Group on
Research Involving the Protected Classes

To address the lack of oversight of research involving
individuals who lack consent capacity in New York
State, in 1990 the New York State Office of Mental
Health (OMH), the state agency that supervises psychiatric facilities, promulgated regulations intended
to allow residents of OMH facilities — both adults and
minors — who lack consent capacity to participate in
research protocols. The regulations’ stated purpose
was to “ensure the protection of patients who participate in research while simultaneously facilitating
research into the very disorders from which they suffer
and which underlie their impairment.”5 Six patients
who had been adjudicated mentally incapable of giving or withholding consent to participate in medical
research brought an action against OMH challenging the regulations.6 The district court found that
the regulations had been improperly promulgated
by OMH because the New York State Department of
Health had the exclusive responsibility of overseeing
all human subjects research in New York.
OMH appealed, and the appellate court upheld the
district court’s finding that OMH did not have authority to promulgate regulations governing human subjects research. The court went further, however, and
held that the regulations violated the due process
clauses of the New York State Constitution and the
Fourteenth Amendment of the U.S. Constitution, as
well as the state’s common law rights to privacy and
personal autonomy. This latter holding was based on
the finding that the OMH regulations failed to provide
for adequate notice and review procedures for individuals who were found to lack consent capacity and
could be enrolled in research protocols. Moreover, the
court found that by permitting research that involved
more than minimal risk, the regulations struck an
improper balance between the “interests of researchers and the rights of the subjects.”7
One year later, the highest New York court held that
the section of the appellate court’s decision related to
the constitutional and common law rights of individuals who lack consent capacity was an “inappropriate
advisory opinion.” 8 Thus, only the court’s reasoning that OMH was not authorized to oversee human
subjects research in New York State is still good law.
Nevertheless, many state agencies — even outside of
New York — have been hesitant to provide guidance
or regulations to include individuals who lack consent

In response to the T.D. litigation, in 1998, the New
York State Department of Health commissioned an
advisory work group to develop regulations authorizing research involving individuals with decisional
incapacity and to address the concept of surrogate
consent to research. The work group released a draft
report entitled Recommendations on the Oversight
of Human Subject Research Involving the Protected
Classes (the NYSAWG report).9 The report proposed
specific and substantial regulatory language for the
Department of Health, including investigator and IRB
responsibilities, requirements for informed consent,
procedures for assessing capacity of potential research
subjects, surrogate authorization, use of research
advance directives, special safeguards to protect the
rights and well-being of research subjects, and reporting requirements. Specifically, it recommended allowing surrogate consent to certain kinds of research that
offers no prospect of direct benefit presenting “minimal risk” or a “minor increase over minimal risk,” and
allowing participation in research that offers no prospect of direct benefit presenting “more than a minor
increase over minimal risk” in special circumstances
with additional safeguards in place.
The report was distributed to over 500 interested
parties for comment. Although the Department of
Health considered revisions to the report in response
to comments and the final decision in T.D., revised
recommendations were never released. In 2000, the
resignation of the former Commissioner of Health,
Barbara Ann DeBuono, and appointment by Governor Pataki of a successor, Antonia C. Novello, “who
would naturally require time to familiarize herself
with the issues,” led to a “delay” in taking next steps
with the proposed regulations.10 Further, “sharp criticism from both advocates and researchers,” including
the state Medical Society (“a powerful lobbying group
in Albany”11), was credited for state inaction.12 The
Department of Health never acted on the report, nor
did it promulgate any regulations regarding the conduct of human subjects research in New York State.
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III. The Task Force on Life and the Law’s
Report and Recommendations for Research with
Human Subjects Who Lack Consent Capacity
In the absence of rules at both the federal and state
level to ensure consistently ethical conduct of research
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involving adults lacking consent capacity, IRBs, investigators, research institutions, and other stakeholders
appealed to the New York State Department of Health
for guidance on how to conduct research involving this
vulnerable population. The Department of Health, in
turn, asked the New York State Task Force on Life and
the Law (the Task Force) to analyze the legal and ethical dimensions of allowing adults who lack consent
capacity in research protocols subject to New York
State oversight. Established by Executive Order in
1985, the Task Force is composed of approximately 23

research includes individuals who lack consent capacity.
Noting its advisory rather than controlling status, the
Task Force focused on the court’s emphasis on research
subjects’ autonomy and dignitary rights.
To address the significant inconsistency in the oversight and conduct of research involving individuals
who lack consent capacity, the Task Force drafted a set
of legal and ethical guidelines regarding the conduct
of research in New York State involving this particular
population.13 An underlying goal of the work was to
ensure that research protocols are available to cogni-

In the absence of rules at both the federal and state level to ensure consistently
ethical conduct of research involving adults lacking consent capacity, IRBs,
investigators, research institutions, and other stakeholders appealed to the
New York State Department of Health for guidance on how to conduct research
involving this vulnerable population. The Department of Health, in turn, asked
the New York State Task Force on Life and the Law (the Task Force) to analyze
the legal and ethical dimensions of allowing adults who lack consent capacity
in research protocols subject to New York State oversight.
Governor-appointed leaders in the fields of religion,
philosophy, law, medicine, nursing, and bioethics.
The Task Force began its endeavor in December
2007 by disseminating a survey to approximately
300 New York IRB chairs and members. The survey
requested information about institutions’ practices, if
any, for conducting research involving the cognitively
impaired, and views on the regulatory landscape.
More than 100 responses provided a detailed and useful qualitative account of research practices in New
York and indicated a need for guidelines to ensure
consistently ethical research practices.
In its examination of the issues associated with
research involving cognitively impaired adults, the Task
Force reviewed medical and policy literature on human
subjects research, informed consent, surrogate consent,
capacity assessment, risk-benefit analysis, research protections, adverse events, and related topics. It conducted
extensive legal research of federal and state regulatory standards, including New York’s, and case studies
pertaining to human subjects research involving the
cognitively impaired. The Task Force analyzed previously-released reports, recommendations, and draft
regulations on human subjects research by the Department of Health and the public comments to these efforts,
including the NYSAWG report. It also took into account
the controversial advisory opinion in T.D., in which the
court addressed the need for special protections where
concussions and sports • fall 2014

tively impaired individuals so that they may reap the
benefits of research and share its risks and burdens
like their non-cognitively impaired peers, while also
ensuring the appropriate level of protections.
Unlike the NYSAWG report, which proposed the
promulgation of specific regulations pursuant to New
York State law,14 the Task Force’s report proposed
guidance — recommendations for IRBs, investigators,
institutions, and legally authorized representatives
(LARs) for the ethical conduct of research involving
individuals who lack consent capacity. The Task Force
encouraged voluntary adherence to these recommendations for all human subjects research involving
adults lacking full consent capacity conducted in New
York State. Moreover, in developing its guidance, the
Task Force considered and declined to recommend
legislation governing research involving individuals
who lack consent capacity. It concluded that because
existing law permits research involving this population, no statutory change was needed.
In its report, the Task Force made a number of
important and, in some cases, unique recommendations regarding adults who lack consent capacity in
human subjects research. For one, in the past, surrogate consent to research in New York State was limited because of uncertainty about who could provide
surrogate consent to participation. The Task Force’s
report relied on the 2010 passage of the Family Health
385

IND EPEND ENT

Care Decisions Act (FHCDA), which changed the
legal landscape by permitting surrogate consent to
health care. The surrogate hierarchy contained in the
statute thus opened up the field of research requiring
surrogate consent in New York State.15
In addition, and probably most importantly, the
Task Force recommended that, in rare circumstances,
adults who lack consent capacity may be enrolled in
research that presents more than a minor increase over
minimal risk that offers no prospect of direct benefit,
provided that a number of significant safeguards and
protections are in place.16 In such cases, for research
with a minor increase over minimal risk and no prospect of direct benefit to the participant, the Task Force
recommended that IRBs may approve such studies
only if the research is vitally important to further the
understanding of the etiology, prevention, diagnosis,
pathophysiology, or alleviation or treatment of a condition or disorder that affects the research population, and if the risks are reasonable in relation to the
research’s “vital importance.” Furthermore, IRBs may
approve such studies only if they require mandatory
rigorous procedures and oversight for enrollment and
monitoring of participants through the use of safeguards, including an independent consent monitor
(ICM) and a medically responsible clinician (MRC).
For research with more than a minor increase over
minimal risk and no prospect of direct benefit to the
participant, IRBs may approve such studies in only
two circumscribed circumstances: where the potential participants have a previously executed research
advance directive or in special situations with notification to the Department of Health and use of a special
review panel.
The latter circumstance would require an alternative approval process consisting of several steps: (1)
IRB review, (2) Department of Health notification by
the IRB and possible referral by the Department of
Health to a special review panel, and (3) an IRB decision to approve or reject the research protocol. For a
protocol to be considered under this alternative process, the IRB must first examine whether the research
is of vital importance. In addition, although this type
of research protocol must be labeled as offering no
prospect of direct benefit, for some research participants, a remote possibility exists that they may benefit from the research or from the knowledge gained.
In such cases, the IRB must consider whether this
remote possibility of benefit exists for potential participants and weigh it against the potential risks of the
protocol. Furthermore, the IRB should ensure that the
study requires rigorous procedures and oversight for
enrollment and monitoring of participants through
the use of safeguards, including an ICM and MRC.
386

Under step two of the process, the IRB should
notify the Department of Health. At its discretion,
the Department may: (1) reject the study (and thus
the research could not be approved by the IRB), (2)
approve the study (whereby the research could be
approved by the IRB), or (3) convene a special review
panel of experts who will examine the study and issue
recommendations to the IRB on whether the study
should be approved.17 If the Department of Health
decides that a special review panel must examine the
protocol, after the special panel has made its recommendations, the Department should refer the protocol back to the IRB for review, and the IRB will
make the final determination based on the panel’s
recommendations.
Further, acknowledging the appellate court’s opinion in T.D., the Task Force recognized that a potential
research participant should be notified and allowed
the opportunity for review of all decisions to involve
him or her in research, including assessments of
capacity. The Task Force emphasized the importance
of procedures for providing notice to the potential research participant and, if necessary, the LAR,
regarding the capacity assessment and opportunities
for objection and review. Researchers should provide
notice to the potential participant and/or LAR that an
assessment will be conducted and the consequences
(if any) of a determination of incapacity. Providing
notice promotes transparency by alleviating any concerns that an individual might be involved in research
without the knowledge of the participant or LAR. It
also demonstrates respect for the prospective participant by presenting an opportunity for the individual
or his/her LAR to object to either the capacity assessment or the results of the evaluation. When capacity
assessments are contested, the most ethical alternative may be to decline to enroll the individual in the
research protocol. However, in some cases, alternatives short of non-enrollment could appropriately deal
with any objection, such as a second capacity assessment. Readily available review procedures allow individuals an opportunity to request further information
or a second opinion where they or their LARs see fit.
Furthermore, steps should be taken during the notification process to ensure that the results of the capacity
assessment remain confidential and that the privacy
of the individual is respected.

Conclusions
Although existing New York State law governs human
subjects research for a subset of research conducted
in the state by providing mechanisms for ensuring
voluntary informed consent for participants and IRB
review of research protocols, it does not provide any
journal of law, medicine & ethics
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special oversight mechanisms for research involving
minimal risks should be permissible under some
adults who lack consent capacity. Despite calls to do
circumstances.”22 To the extent that the Task Force’s
so, federal law also does not provide safeguards or
recommendations deviate from past reports and the
special protections for research involving “mentally
“inappropriate advisory opinion” in T.D., they seek to
disabled persons.”18 The absence of such guidelines or
offset concerns with proposals for significant addiregulations may lead to unethical or unsafe research
tional safeguards and oversight mechanisms.
protocols or the dearth of important research into the
The Task Force’s report may be better received than
broad range of diseases that impair cognition. Despite
past recommendations for two reasons. First, since
the continued absence of rules at both the federal and
the state’s previous efforts to regulate research involvstate level to ensure consistently ethical conduct of
ing the cognitively impaired, a few other states have
research involving adults lacking
consent capacity, such research
continues “in the shadow of the
law.” 19 While some institutions Thus, for entities that previously did not pursue
research with adults lacking consent capacity, the
and investigators are conducting
research with this population with- report endeavors to provide the foundation that
out oversight or guidance, others
are taking an extremely conserva- will enable them to pursue research protocols that
will lead to a better understanding of conditions
tive approach and are excluding
these individuals from research, that impair cognition. For those who already
citing concerns about vulnerability
and exploitation. Without appro- enroll adults who lack consent capacity in research
priately protective but not overly protocols, the report will help them ensure that
burdensome safeguards, this will
consistent and appropriate safeguards are in place to
remain a challenge to the conduct
protect the welfare of these vulnerable individuals.
of ethical research.
Guidance like the Task Force’s
report is becoming increasingly
necessary. In its survey of New York IRB chairs and
passed laws authorizing research with incapacitated
members, the Task Force found that, in the absence of
persons.23 A handful of states have passed laws specificlear guidance, institutions either abstained entirely
cally authorizing research with incapacitated persons,
from research that required surrogate consent or
including California, New Jersey, Virginia, Oklahoma,
engaged in such research despite the lack of clear
and Wyoming.24 Nevertheless, most current laws only
authority. Beyond New York, research involving indiauthorize surrogate consent to research without enuviduals who lack consent capacity occurs, even withmerating any significant safeguards. Second, although
out legal or regulatory oversight. Laws that explicitly
regulatory oversight mechanisms may be more effecauthorize research with incapacitated individuals
tive in ensuring consistent and uniform protections of
are isolated exceptions; in the vast majority of states,
individuals who lack consent capacity in research, the
research with individuals who lack consent capacity
framing of the report as guidance, rather than mandacontinues without any noticeable oversight, including
tory rules, may make the recommendations more palregarding who may consent to research on behalf of
atable — at least initially — to investigators, research
the incapacitated participant. As of 2008, nine states
institutions, IRBs, and other stakeholders. Policy
had statutes that specifically allow family members to
makers may eventually seek to enact mandatory regugive proxy consent on behalf of their incompetent famlatory oversight mechanisms, based on observations
ily members to participate in research, although some
of the success (or lack thereof ) of the guidelines.
of these jurisdictions restrict the use of proxy consent
The Task Force’s recommendations may also serve
to certain populations or certain types of research.20
as a model for research policy in other states and at
Various commentators have opined on the “unsucthe federal level. Importantly, they are more comcessful” proposals of the federal, New York, and Maryprehensive and propose more significant safeguards
land commissions that, in the late 1990s, made recomfor research involving individuals who lack consent
mendations for the inclusion of cognitively impaired
capacity than existing federal and state oversight
individuals in research.21 Like the Task Force’s curmechanisms. Thus, for entities that previously did not
rent recommendations, all three past reports “agreed
pursue research with adults lacking consent capacity,
that no-direct-benefit studies involving more than
the report endeavors to provide the foundation that
concussions and sports • fall 2014
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will enable them to pursue research protocols that
will lead to a better understanding of conditions that
impair cognition. For those who already enroll adults
who lack consent capacity in research protocols, the
report will help them ensure that consistent and
appropriate safeguards are in place to protect the welfare of these vulnerable individuals.
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